Adam D Cohen, MD

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-175
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-615-5853
Fax: 215-615-5887
Education:
BA
Harvard University, 1994.
MD
University of Pennsylvania, 1999.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Multiple Myeloma
Amyloidosis
POEMS syndrome
Monoclonal gammopathies
Waldenstrom's Macroglobulinemia

Description of Research Expertise

Cancer immunotherapy
Vaccines
Cellular therapy
Phase I trials
CAR T cells

Selected Publications

Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander NS, Singh AK, Parker TL, Menter A, Yang X, Parsons BM, Kumar P, Kapoor P, Rosenberg AS, Zonder JA, Faber EA, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV: Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology 21(10): 1317-1330, Oct 2020.

Richardson PG, Lee HC, Abdalla A-O, Cohen AD, Kapoor P, Voorhees PM, Hoos A, Wang K, Baron J, Piontek T, Byrne J, Richmond S, Jewell RC, Opalinska J, Gupta I, Lonial S: Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer Journal 10(10): 106, Oct 2020.

Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M.: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Journal for Immunotherapy of Cancer 8(2): e000734, Jul 2020.

AD Cohen, N Raje, J Fowler, K Mezzi, EC Sctoo, MV Dhodapkar: How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clinical Cancer Research 26(7): 1541-1554, Apr 1 2020.

Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren E, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie BG, Orlowski RZ: Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clin Cancer Res Apr 16 2020 Notes: doi: 10.1158/1078-0432.CCR-19-1997. Online ahead of print.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah A-O, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facun T, Hulin C, Kortum M, Rodriguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Pointek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD: Belantamab mafotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm randomised, open label, phase 2 study. Lancet Oncology 21(2): 207-221, Feb 2020.

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker K, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH: CRISPR-engineered T cells in patients with refractory cancer. Science 367(6481): eaba7365, Feb 28 2020.

Cohen AD: Myeloma: next-generation immunotherapy. Hematology. American Society of Hematology Education Program. 2019(1): 266-272, Dec 2019.

Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney A, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS. : Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer Immunol Res 7(10): 1633-1646, Oct 7 2019.

Cohen AD: CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update. American Society of Clinical Oncology Educational book 38: e6-e15, May 2018.

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson Jr. LD, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD: Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncology 19(12): 1641-1653, Dec 2018.

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation. The American Society for Clinical Investigation, 129(6): 2210-2221, Mar 2019.

Susanibar Adaniya SP, Cohen AD*, Garfall AL*: Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. American Journal of Hematology 94(S1): S28-S33, May 2019 Notes: *co-senior authors.

Trudel, S, Lendvai, N, Popat, R, Voorhees, P M., Reeves, B, Libby, E N., Richardson, P G., Hoos, A, Gupta, I, Bragulat, V, He, Z, Opalinska, J B., Cohen, A D.: Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer 9(4): 37, Mar 20 2019.

Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ.: Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunol Res 7(4): 658-669, Apr 2019 Notes: Co first authors.

Cornell RF, Ky B, Weiss BM, Dahm C, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O’Quinn R, Savona MR, Slosky D, Smith AM, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D. : Prospective Study of Cardiac Events during Proteastome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol 37(22): 1946-1955, Aug 2019.

Fajgenbaum DC, Langan R-A, Japp AS, Shilling D, Partridge HL, Pierson SK, Singh A, Ruth JR, Nabel CS, Stone K, Chaturvedi V, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Cohen AD, Krymskaya V, Rubenstein A, Betts M, Kambayashi T, Jordan MB, van Rhee F, Uldrick TS. : Identifying and Targeting Pathogenic PI3K/AKT/mTOR Signaling in IL-6-blockade-refractory Idiopathic Multicentric Castleman Disease J Clin Invest 130(10): 4451-63, Aug 2019.

Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M, Levine B, Siegel D, Stadtmauer E,Vogl D, Waxman A, Rapoport A, Milone M, June C, Melenhorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Adv 3(19): 2812-2815, Oct 8 2019.

Cohen AD, Garfall AL, Dogan A, Lacey SF, Martin C, Lendvai N, Vogl DT, Spear M, Lesokhin AM: Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies Blood Advances 3(16): 2487-2490, Aug 2019.

back to top
Last updated: 12/26/2020
The Trustees of the University of Pennsylvania